For Andrew Hall, a veteran of Big Pharma-turned biotech builder, he has spent much of his recent career operating inside those constraints — and learning how to lead through them. Today, as CEO of ...

Poor/fair health status correlated with greater cost-related trade-offs, indicating those with higher healthcare utilization are simultaneously more exposed to affordability-driven nonadherence and ...

FDA now permits Arexvy for adults 18–49 with elevated RSV risk from conditions such as chronic cardiopulmonary or renal disease, obesity, and diabetes. Epidemiology in U.S. adults 18–49 includes ...

“At the early stage, you’ve got to be hands-on, get involved with everything and everyone, and really understand your own limitations,” he added. For emerging biotechs, this combination of strategic ...

In today's Pharmaceutical Executive Daily, a new West Health-Gallup survey finds that more than 82 million Americans have cut back on daily expenses to cover healthcare costs, the FDA expands the ...

In today's Pharmaceutical Executive Daily, Senate Democrats press major pharmaceutical companies for transparency on the ...

Testing identified significant impurity formation when tirzepatide is compounded with B12 variants, suggesting chemical incompatibility that is not evaluated under FDA review pathways. Uncertainty ...

In most life sciences organizations, each function has built its own analytics environment with separate data models, dashboards, and reporting processes. Sales teams often rely on one set of ...

Hennemand explains that Sail started in oncology but quickly pivoted to autoimmune disorders due to the suitability of RNA-based CAR T therapies. Hennemand highlights the advantages of RNA technology, ...

Novo Nordisk issued a response to an FDA warning letter that cited serious violations in how the company tracked and reported adverse drug events for several of its medicines. Included in the ...

For full-year 2025, 58 biotech deals worth $65.9 billion were completed compared with 73 deals worth $109 billion in all of 2024. This represents a major decline in total dollar volume and the number ...

In today's Pharmaceutical Executive Daily, the FDA issues new draft guidance aimed at reducing the cost and complexity of biosimilar development, Novo Nordisk responds to an FDA warning letter ...